55 episodes

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Medical Industry Feature ReachMD

    • Science

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

    Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know

    Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know

    Host: Matt Birnholz, MD

    Guest: Gary Cohen, MD


    What’s the difference between a generic drug and biosimilar? How does the FDA define biosimilarity? And how are biosimilars developed? Get answers to these and other questions with Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC, in the first episode of this two-part video.
    ©2020 Amgen Inc. All rights reserved. USA-CBU-80726 10/20

    Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know

    Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know

    Host: Matt Birnholz, MD

    Guest: Gary Cohen, MD


    Biosimilars undergo a rigorous evaluation process to ensure high quality and no clinically meaningful difference between biosimilars and the reference product. To learn more about how biosimilar clinical trials are designed to confirm biosimilarity, tune in to the second episode of this two-part series featuring Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC.
    ©2020 Amgen Inc. All rights reserved. USA-CBU-80729 10/20

    Key Considerations for Initiating a Chronic Lymphocytic Leukemia Therapy

    Key Considerations for Initiating a Chronic Lymphocytic Leukemia Therapy

    Guest: Lisa Nodzon PhD, ARNP, AOCNP


    No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or
    relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.

    Looking Out for Neutropenia in Chronic Lymphocytic Leukemia

    Looking Out for Neutropenia in Chronic Lymphocytic Leukemia

    Guest: Lisa Nodzon PhD, ARNP, AOCNP


    Both the disease itself and the treatments for chronic lymphocytic leukemia (CLL) can cause neutropenia, which is why Dr. Lisa Nodzon from the Moffitt Cancer Center is here to discuss neutropenia in relation to CLL treatment with venetoclax.

    Prevalence of Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    Prevalence of Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    Host: Richard K. Bogan, MD


    While positive airway pressure is the standard of care treatment for obstructive sleep apnea (OSA), it may not always be enough to address the excessive daytime sleepiness (EDS) that some patients experience. In fact, in one study, up to 34 percent of patients with OSA still reported EDS (Epworth Sleepiness Score ≥10) despite more than 5 hours of CPAP use a night.
    Here, Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc., sheds light on the prevalence of EDS in OSA. Specifically, Dr. Bogan discusses key data that has raised important observations about how commonly EDS may persist even when patients adhere to CPAP therapy.
    This promotional, non-CME program is intended for U.S. physicians treating OSA.
    Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
    © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
    US-SLE-2000467 Rev0920

    Pathophysiology of Obstructive Sleep Apnea & Its Role in Excessive Daytime Sleepiness

    Pathophysiology of Obstructive Sleep Apnea & Its Role in Excessive Daytime Sleepiness

    Guest: Richard K. Bogan, MD


    Emerging science can help us better understand the link between obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS). While many factors, such as insufficient sleep, medication, or comorbid disorders, can cause your patients with OSA to feel sleepy, chronic sleep disruption and chronic intermittent hypoxia associated with OSA may also contribute to EDS.
    Here to discuss the important physiologic changes to gray and white matter that may occur in OSA and lead to EDS is Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc.
    This promotional, non-CME program is intended for U.S. physicians treating OSA.
    Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
    © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
    US-SLE-2000467 Rev0920

Top Podcasts In Science

Listeners Also Subscribed To

More by ReachMD